Skip to search formSkip to main contentSkip to account menu

moexiprilat

Known as: 2-(2-(1-carboxy-3-phenylpropyl)amino-1-oxopropyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
A non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Moexiprilat competitively inhibits ACE, thereby… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
High-performance liquid chromatography combined with a UV absorbance detector and electrospray ionization mass spectrometer is… 
2003
2003
ACE inhibitors induce metabolic changes and exert cardioprotective and vasoprotective properties, some of which cannot be… 
1997
1997
The effects of 2‐2‐(1‐(ethoxycarbonyl)‐3‐phenylpropyl)‐[amino‐oxopropyl]−6,7‐dimethoxy‐1,2,3,4‐tetrahydroisoquinoline‐3… 
1997
1997
The pharmacodynamic and toxicological profile of the new angiotensin converting enzyme (ACE) inhibitor moexipril (CAS 82586-52-5… 
1996
1996
Moexipril is a new, long-acting angiotensin-converting enzyme (ACE) inhibitor. In contrast to captopril, it is a prodrug of the… 
1995
1995
To assess the efficacy and time‐dependent effects of once‐daily moexipril, a nonsulfhydryl ester prodrug of the angiotensin… 
1993
1993
In the presence of indomethacin (10 microM) and without previous exposure to bradykinin, two angiotensin-converting enzyme (ACE… 
1992
1992
We have investigated the effects of angiotensin-converting enzyme (ACE) inhibitors on intracellular Ca2+ levels in human cultured…